01 Expansion of Domestic Biologics Manufacturing in Developing Regions A key trend driving growth in the erythropoietin drugs market is the focus on building local biologics manufacturing capabilities in developing countries. For example, in October 2023, Indonesia’s Ministry of Food and Drug Safety (BPOM) approved Efepoetin alfa, a long-acting EPO developed by Genexine, a leading domestic pharmaceutical company.This milestone highlights the shift toward localized production, which enhances treatment affordability, ensures consistent supply, reduces reliance on imports, and strengthens the domestic biopharmaceutical sector, collectively supporting market expansion in emerging regions.
02 Shift from Intravenous to Subcutaneous Administration of Erythropoietin Drugs The shift from intravenous to subcutaneous administration of erythropoietin drugs is a key trend for market growth. Subcutaneous injections, such as those used with long acting formulations like methoxy polyethylene glycol-epoetin beta (Mircera), allow for less frequent dosing, reduced clinic visits, and improved patient comfort. This trend is enhancing treatment adherence and convenience, driving broader adoption and supporting sustained market growth globally.
01 Rising Prevalence of Cancer-Related Anemia The increasing number of people suffering from cancer-related anemia is a key growth driver for the erythropoietin drugs market. According to the American Cancer Society, around 65% of patients across various cancer types and 25.7% of those with solid tumors suffer from anemia, representing a notable population in need of treatment.Thus, the rising global incidence of cancer is further amplifying demand for effective anemia management therapies, driving the adoption of erythropoietin drugs and contributing to overall market expansion.
01 High Cost of Erythropoietin Therapies A major restraint in the erythropoietin drugs market is the high cost of treatment, which limits patient access, particularly in low and middle-income countries. According to the International Society of Nephrology, annual therapy for chronic kidney disease-related anemia exceeded USD 8,000 per patient.Consequently, this high expense restricts widespread adoption of erythropoietin therapies and remains a key barrier to global market growth.
01 Home-Based Anemia Management Programs Create New Scope for the Market The integration of home-based anemia management programs is creating an opportunity for the erythropoietin drugs market. Various hospitals in the U.S. and Europe implemented patient-administered subcutaneous erythropoietin injection programs, allowing patients to self-administer therapy at home. This approach reduces hospital visits, lowers healthcare costs, and improves treatment adherence, thereby providing new scope for patient-centered erythropoietin therapies.
June 2026 Amgen expanded its anemia treatment portfolio with continued commercialization of erythropoiesis-stimulating agents (ESAs) used in chronic kidney disease and oncology-related anemia management. The company focused on improving access to established erythropoietin-based therapies.
March 2026 Roche expanded its hematology and supportive care portfolio with advancements in anemia management solutions. The company continued supporting treatment approaches involving erythropoietin-based therapies for patients requiring red blood cell production stimulation.
January 2026 Johnson & Johnson expanded its supportive oncology care portfolio with continued focus on anemia management therapies. The initiatives support healthcare providers in managing treatment-related anemia through established erythropoietin drug solutions.
October 2025 Biocon Biologics expanded its biosimilar erythropoietin portfolio with increased availability of recombinant erythropoietin products across international markets. The expansion supports broader access to affordable anemia treatments.